Lars Bruening, CEO, Bayer UK & Ireland
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Address: Boehringer Ingelheim Limited, Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS, United Kingdom ,United Kingdom
Tel: +44 (0) 1344 424 600
Web: http://www.boehringer-ingelheim.co.uk/
Boehringer Ingelheim is a family owned company whose distinctly independent structure means that we are not constrained by the short-term needs of individual shareholders and can focus on the future with long-term strategies of vision and leadership. Boehringer Ingelheim was founded in 1885 by Albert Boehringer and remains a familyowned company. Today we are the fastest growing company amongst the world’s 15 leading pharmaceutical companies.
Annual sales are €12.7 billion worldwide (2009) and 21% of the net sales from its Prescription Medicine business is invested into research and development. The company now employ more than 41,500 people and is committed to remaining family-owned. Albert’s great grandson, Christian Boehringer, is the Chair of the Shareholders’ Committee which manages 142 affiliated companies in 50 countries around the globe. Our headquarters remain in Ingelheim, near Frankfurt in Germany.
Boehringer Ingelheim’s vision, ‘Value through Innovation’, mirrors the founder’s own belief in the importance of innovative thinking and that, as well as being financially profitable, products should be pioneering and of genuine benefit to patients. This independent status frees the company from stock market expectations, and allows for long-term strategies, rather than short-term priorities.
In the United Kingdom, Boehringer Ingelheim was established in 1962 and is one of the fastest growing pharmaceutical companies in the UK, with total sales of £388 million in 2009 (independent audit). The business focuses on clinical research, data management, sales and marketing.
Boehringer Ingelheim is involved in three key healthcare areas: Prescription Medicines, Over-The-Counter (OTC) products and Animal Health. In each sector, the company has world-class medicines to treat patients.
The company has a reputation for providing effective products for the treatment of chronic obstructive pulmonary disease (COPD), heart attack, secondary stroke prevention and treatment, high blood pressure, thromboembolic disease, HIV/AIDS, Parkinson’s disease, arthritis and pain relief in cancer.
These products are supported by a wide range of services, designed to help the medical profession deliver the best possible healthcare to patients.
This underlines Boehringer Ingelheim’s commitment to improving health and quality of life in the UK.
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s…
Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to…
One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical…
Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid…
Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and…
The new AI tech from Google’s DeepMind can diagnose over 50 retinal diseases with more accuracy than your optometrist. Research conducted by Nature Medicine found that a ground-breaking artificial intelligence system developed…
Adaptimmune, a British-based biotech company born out of the University of Oxford has a solid research base in the UK and manufactures its T-Cells in the US. Its CEO, James…
Richard Erwin, general manager of Roche Products Ltd in the UK, speaks out about the challenges facing the company, from market access to uptake of innovation, to collaborating with diverse…
With a strong historic footprint in Edinburgh, Canon Medical Systems has based one of its global R&D centres in Scotland from where it develops software for its devices. Ken Sutherland,…
After 30 years in the cell therapy space, Dr Michael Leek founded TC BioPharm in Scotland. Within four years the company has forged major partnership deals and advanced its CAR…
Recently appointed as general manager & vice president of Gilead’s UK and Ireland operations, Hilary Hutton-Squire highlights the uniqueness of the UK’s healthcare system, its expertise in life sciences and…
See our Cookie Privacy Policy Here